Herpes zoster after autologous hematopoietic stem cell transplantation

• Main Authors: Kelli Borges dos Santos, Rafaela Souto e Souza, Angelo Atalla, Abrahão Elias Hallack-Neto
• Format: Article
• Language: English
• Published: Elsevier
• Series: Revista Brasileira de Hematologia e Hemoterapia
• Subjects: Transplant of hematopoietic stem cells; Autologous; Herpes zoster; Prevention and control
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000400298&lng=en&tlng=en

ABSTRACT Background: The autologous hematopoietic stem cell transplantation procedure involves immunosuppression of the patient. Thus, the patient has an elevated risk for several diseases, such as infections with the varicella-zoster virus. Prevention protocols have been proposed based on the use of acyclovir from the first day of conditioning, and maintaining this drug for 30-100 days after the procedure or for as much as one year. The objective of this work was to evaluate the incidence of herpes zoster after autologous transplantations related to the early suspension of acyclovir. Methods: A retrospective study was carried out based on the collection of data from 231 medical records of transplant patients in the Bone Marrow Transplant Unit of the teaching hospital of the Universidade Federal de Juiz de Fora in the period between 2004 and 2014. Results: Fourteen (6.1%) patients had herpes zoster in the post-transplant period on average within six months of the procedure. Patients with multiple myeloma (64.3%) were the most affected. There was a statistically significant difference in the age of the patients, with older individuals having a greater chance of developing the infection (p-value = 0.002). There were no significant differences for the other variables analyzed. Conclusion: The early suspension of acyclovir can be safe in patients who receive autologous hematopoietic stem cell transplants. However some groups may benefit from extended prophylaxis with acyclovir, particularly older patients and patients with multiple myeloma.